225Ac-TBM

225Ac-TBM is an investigational radiopharmaceutical drug composed of actinium-225 (an alpha-emitting radionuclide) conjugated to a tumor-targeting biomolecule (TBM). The TBM component is typically a monoclonal antibody or peptide designed to selectively bind to specific antigens expressed on the surface of cancer cells. Once bound, the actinium-225 delivers highly cytotoxic alpha radiation directly to the targeted tumor cells, causing double-stranded DNA breaks and cell death while minimizing damage to surrounding healthy tissue. This targeted alpha therapy approach is being explored for various malignancies, particularly hematologic cancers and solid tumors that express the relevant antigen. The precise identity of "TBM" in this context may refer generically to a "tumor-binding molecule," as no specific antibody or peptide named "TBM" was identified in current literature; thus, it likely represents a platform or placeholder for different targeting agents conjugated with actinium-225.

Other names

[225Ac]Ac-TBM225Ac-DOTBM225Ac-DOTMP